{ "schemaVersion": 2, "eyebrow": "Structural Heart Disease", "title": "Tricuspid Regurgitation", "summary": "Manage tricuspid regurgitation by confirming severity with an integrated echocardiographic assessment, defining primary, atrial-functional, ventricular-functional, or lead-related mechanisms, treating congestion and upstream disease, and referring symptomatic severe disease before advanced right ventricular, renal, or hepatic dysfunction limits procedural benefit.", "seoDescription": "Physician guide to tricuspid regurgitation evaluation, echocardiographic severity, mechanism, congestion management, surgery, and transcatheter repair.", "clinicalQuestion": "How should physicians evaluate mechanism and severity of tricuspid regurgitation and select medical, surgical, or transcatheter treatment?", "specialty": "Cardiology", "audience": "U.S. physicians and medical trainees", "tags": [ "tricuspid regurgitation", "severe tricuspid regurgitation", "functional tricuspid regurgitation", "tricuspid TEER", "TriClip", "right-sided heart failure", "lead-related tricuspid regurgitation" ], "keyTakeaways": [ "Suspected severe TR requires comprehensive 2-dimensional and Doppler echocardiography to grade regurgitation and define valve morphology, annular size, and right-ventricular size and function. [5]", "Severe TR is supported by vena contracta diameter greater than 0.7 cm, effective regurgitant orifice area of at least 40 mm2, regurgitant volume of at least 45 mL, hepatic-vein systolic flow reversal, and a dense dagger-shaped continuous-wave Doppler signal. [5][13]", "Separate primary structural disease from functional TR due to annular and right-ventricular dilation; atrial fibrillation, pulmonary hypertension, left-sided valve disease, and transvenous device leads each change the corrective strategy. [8][6]", "Refer symptomatic severe TR early to a multidisciplinary valve center; late presentation with marked right-sided chamber distortion, tethering, and large coaptation gaps can reduce feasibility of repair. [17]", "In symptomatic severe TR, transcatheter edge-to-edge repair improved health status, 6-minute walk distance, and TR reduction at 1 year versus medical therapy, without a 12-month mortality or tricuspid-surgery difference in the randomized TRILUMINATE cohort. [18]" ], "sections": [ { "id": "triage-and-initial-assessment", "eyebrow": "First decision", "heading": "Identify congestion and establish whether TR is clinically consequential", "intro": "Prioritize hemodynamics, systemic venous congestion, and anatomic mechanism rather than jet appearance alone.", "paragraphs": [ "In a patient with edema, ascites, elevated jugular venous pressure, hepatic congestion, or recurrent right-sided heart-failure admissions, obtain transthoracic echocardiography with comprehensive 2-dimensional and Doppler assessment. The study should confirm TR severity and evaluate leaflet morphology, annular dimensions, right-atrial and right-ventricular enlargement, and right-ventricular systolic function. [5]", "Interpret severe TR as a systemic venous-congestion lesion: TR increases right-atrial pressure and reduces venous return, contributing to right-sided heart-failure physiology. Hepatic-vein systolic flow reversal identifies severe TR; leftward bowing of the interatrial septum supports elevated right-atrial pressure or volume overload. [4][13]", "Obtain renal and hepatic function tests when severe TR is suspected clinically or echocardiographically, particularly before valve intervention. Isolated severe tricuspid-valve surgery should be considered before advanced functional limitation and hepatic dysfunction develop, because late organ dysfunction and advanced right-ventricular remodeling narrow the therapeutic window. [8]" ], "bullets": [ "Urgently reassess severe TR with escalating systemic congestion, worsening renal or hepatic indices, or progressive right-sided chamber enlargement, because these findings support advancing referral rather than continued observation. [8][17]", "Do not use a single color-Doppler metric to exclude severe TR; integrate structural, color, Doppler, and venous-flow findings. [5]" ], "subsections": [], "table": { "caption": "Echocardiographic findings supporting severe tricuspid regurgitation and their clinical interpretation. [5][13]", "columns": [ "Finding", "Severe TR threshold or pattern", "Interpretation and next action" ], "rows": [ [ "Central color jet area", ">10 cm2 [5]", "Supports severe TR; integrate with quantitative and venous-flow parameters. [5]" ], [ "PISA radius", ">0.9 cm [5]", "Supports severe TR when the jet is suitable for PISA-based assessment. [5]" ], [ "Vena contracta", ">0.7 cm [5]", "Quantitative severe-TR criterion; reassess mechanism and right-heart remodeling. [5]" ], [ "Effective regurgitant orifice area", "≥40 mm2 [5]", "Quantitative severe-TR criterion. [5]" ], [ "Regurgitant volume", "≥45 mL [5]", "Quantitative severe-TR criterion. [5]" ], [ "Continuous-wave Doppler", "Dense, dagger-shaped TR signal [5]", "Suggests rapid right atrial-right ventricular pressure equalization in severe TR. [5]" ], [ "Hepatic-vein Doppler", "Systolic flow reversal [5][13]", "Strong corroborating marker of severe TR and venous congestion. [5][13]" ] ] } }, { "id": "mechanism-directed-workup", "eyebrow": "Etiologic branch", "heading": "Classify TR mechanism before selecting an intervention", "intro": "The mechanism determines whether the primary target is the valve, right-heart loading condition, rhythm substrate, or device lead.", "paragraphs": [ "Classify TR as primary (organic) when leaflet or subvalvular structural pathology is present, versus functional when valve leaflets are structurally normal but malcoaptation results from annular and right-ventricular dilation. Functional TR is the most common acquired form; rheumatic disease is the most common cause of organic tricuspid-valve disease in the cited surgical review. [8]", "For functional TR, determine whether the phenotype is predominantly ventricular-functional or atrial-functional. Right-ventricular dilation and dysfunction with annular dilation favor ventricular-functional TR, often in the setting of pulmonary hypertension or left-sided valvular disease. Predominant right-atrial and annular dilation in atrial fibrillation favors atrial-functional TR. This distinction informs whether correcting upstream left-sided disease, pulmonary vascular loading, rhythm-related atrial remodeling, or the valve lesion itself is the more plausible therapeutic lever. [8][17]", "Review all prior transvenous cardiac implantable electronic device procedures and interrogate lead course on echocardiography when a lead traverses the tricuspid valve. Lead-related TR affects an estimated 20% to 30% of cardiac implantable electronic devices; establish whether the lead is plausibly contributing to leaflet interference or whether TR is instead functional from chamber remodeling before choosing a valve procedure. [6]" ], "bullets": [ "Primary TR: document leaflet or subvalvular pathology and assess surgical repair versus replacement strategy in a valve center. [8]", "Functional TR: quantify annular and right-ventricular remodeling, evaluate pulmonary hypertension and left-sided valve disease, and treat the upstream driver while assessing valve-intervention timing. [8]", "Lead-associated TR: involve electrophysiology and the structural-heart team early because lead management may materially affect feasibility and durability of tricuspid intervention. [6]" ], "subsections": [], "table": { "caption": "Mechanism-based framework for tricuspid regurgitation. [8][6][17]", "columns": [ "Mechanism", "Discriminating assessment", "Management implication" ], "rows": [ [ "Primary or organic TR", "Structural leaflet or subvalvular pathology, with or without annular dilation. [8]", "Assess valve repair or replacement before severe functional limitation, hepatic dysfunction, and advanced right-ventricular impairment. [8]" ], [ "Ventricular-functional TR", "Annular and right-ventricular dilation with structurally normal valve; evaluate pulmonary hypertension and left-sided valve disease. [8]", "Address the upstream loading or left-sided lesion and reassess persistent severe TR for valve intervention. [8]" ], [ "Atrial-functional TR", "Right-atrial and annular enlargement in atrial fibrillation, often with progressive malcoaptation. [8][17]", "Control congestion and evaluate early for transcatheter feasibility before chamber distortion, tethering, and coaptation-gap enlargement progress. [17]" ], [ "Lead-related TR", "Transvenous lead across the valve in a patient with new or progressive TR; lead-related TR occurs in 20% to 30% of CIEDs. [6]", "Define the lead's contribution before selecting lead management, surgery, or transcatheter therapy. [6]" ] ] } }, { "id": "medical-management-and-surveillance", "eyebrow": "Stabilization", "heading": "Treat congestion and upstream disease while planning definitive therapy", "intro": "Medical therapy relieves volume overload but does not correct anatomic malcoaptation.", "paragraphs": [ "Use symptom-directed medical management to control volume overload while completing structural evaluation. In severe atrial-functional TR, substantial volume overload can worsen right-atrial and right-ventricular distortion, annular dilation, leaflet tethering, and coaptation gaps; decongestion can therefore improve candidacy assessment for transcatheter edge-to-edge repair. [17]", "Do not allow symptomatic improvement after decongestion to defer evaluation indefinitely when severe TR persists with right-sided remodeling or organ-congestion features. Severe TR is associated with progressive right-heart failure, and late referral is linked to advanced volume overload and anatomy less amenable to repair. [14][17]", "For functional TR, reassess severity after treatment of relevant upstream disease, including left-sided valvular pathology or pulmonary hypertension, because functional TR arises from annular and right-ventricular dilation and may be reversible in some patients. [8]" ], "bullets": [ "At each reassessment, compare systemic congestion, renal and hepatic function, right-sided chamber dimensions, right-ventricular function, and integrated TR severity rather than relying on symptoms alone. [5][8]", "Escalate to a multidisciplinary valve center when symptomatic severe TR remains despite medical optimization, especially before severe hepatic dysfunction or marked right-ventricular impairment. [8][17]" ], "subsections": [], "table": { "caption": "", "columns": [], "rows": [] } }, { "id": "surgical-and-transcatheter-treatment", "eyebrow": "Definitive therapy", "heading": "Select surgery or transcatheter treatment before irreversible right-heart injury", "intro": "Choose intervention through multidisciplinary assessment of symptoms, anatomy, right-ventricular reserve, comorbidity, and procedural risk.", "paragraphs": [ "Consider surgery for isolated severe tricuspid-valve disease before severe functional limitation and hepatic dysfunction, particularly when the right ventricle is markedly enlarged and systolic function is impaired. Surgical risk has historically limited isolated procedures: reported in-hospital mortality for isolated TR surgery is 5% to 13%, and current practice has therefore concentrated surgery in selected candidates. [8][17]", "For symptomatic severe or greater TR in patients considered for transcatheter repair, evaluate leaflet grasping anatomy, tethering, coaptation gap, annular and chamber dilation, and interaction with any transvalvular lead. Advanced longstanding volume overload can enlarge coaptation gaps and leaflet tethering, making transcatheter edge-to-edge repair less feasible; optimize congestion before final screening when possible. [17]", "In the 572-patient randomized TRILUMINATE cohort, TriClip transcatheter edge-to-edge repair was superior to medical therapy for the hierarchical primary endpoint at 1 year (win ratio 1.8; 95% CI, 1.4-2.5), driven primarily by health-status improvement. At 12 months, freedom from all-cause mortality or tricuspid surgery was similar for device and control groups (90.6% versus 89.9%), and annualized heart-failure hospitalization rates were also similar in the full cohort (0.17 versus 0.20 events per patient-year). [18]", "Frame transcatheter edge-to-edge repair as a symptom- and function-oriented intervention with demonstrated improvement in TR reduction, Kansas City Cardiomyopathy Questionnaire score, and 6-minute walk distance at 1 year. In TRILUMINATE, 52.3% of device-treated patients achieved at least a 15-point improvement in health status; treatment selection should therefore prioritize symptomatic severe disease with appropriate anatomy rather than an expectation of proven short-term mortality benefit. [18]" ], "bullets": [ "Surgical pathway: favor early assessment for isolated severe disease when operative candidacy is acceptable and before hepatic dysfunction or advanced right-ventricular failure. [8]", "Transcatheter pathway: consider symptomatic severe or greater TR when a multidisciplinary team judges anatomy suitable and surgical risk or clinical profile favors a less invasive approach. [17][18]", "Procedural counseling: distinguish durable TR reduction and quality-of-life benefit from mortality and hospitalization outcomes, which were not different at 12 months in the full randomized TRILUMINATE cohort. [18]" ], "subsections": [], "table": { "caption": "Practical selection framework for definitive TR intervention. [8][17][18]", "columns": [ "Clinical situation", "Preferred next action", "Key tradeoff" ], "rows": [ [ "Isolated severe organic TR with acceptable operative candidacy", "Refer for surgical assessment before severe limitation, hepatic dysfunction, marked RV enlargement, and RV systolic impairment. [8]", "Surgery offers definitive valve treatment but isolated-procedure in-hospital mortality has been reported at 5% to 13%. [17]" ], [ "Symptomatic severe functional TR with persistent congestion after upstream-disease management", "Multidisciplinary valve-center evaluation for anatomic suitability and timing of valve intervention. [8][17]", "Delay can worsen annular dilation, tethering, and coaptation gap, reducing repair feasibility. [17]" ], [ "Symptomatic severe or greater TR with suitable edge-to-edge anatomy", "Consider transcatheter edge-to-edge repair plus medical therapy. [18]", "At 1 year, benefit was chiefly health status, exercise capacity, and TR reduction; mortality and tricuspid-surgery freedom were similar to control. [18]" ], [ "Transvenous lead crossing tricuspid valve", "Define lead-related contribution with electrophysiology and structural-heart input before valve intervention. [6]", "Lead interaction can affect mechanism and procedural feasibility. [6]" ] ] } }, { "id": "follow-up-after-referral-or-intervention", "eyebrow": "Monitoring", "heading": "Monitor the parameters that signal residual congestion or procedural failure", "intro": "Follow clinical congestion and right-heart structure alongside residual TR.", "paragraphs": [ "After medical optimization or valve intervention, reassess integrated TR severity with echocardiography, including vena contracta, Doppler jet characteristics, hepatic-vein flow, inferior vena cava findings, right-sided chamber size, and right-ventricular function. Hepatic-vein systolic reversal and a dense dagger-shaped continuous-wave Doppler signal remain useful markers of severe residual TR. [5][13]", "Track systemic venous-congestion consequences with renal and hepatic function testing, physical examination for edema or ascites, and functional status. Worsening congestion or progressive right-sided enlargement despite treatment should trigger repeat multidisciplinary review rather than serial medical escalation alone. [8][17]", "After transcatheter edge-to-edge repair, assess residual TR and patient-centered response using functional capacity and health status; the randomized trial demonstrated improvements in Kansas City Cardiomyopathy Questionnaire score and 6-minute walk distance at 1 year, making both appropriate outcome measures when evaluating clinical benefit. [18]" ], "bullets": [ "Repeat valve-center review for recurrent severe TR, escalating systemic congestion, progressive hepatic or renal dysfunction, or anatomy that may have evolved beyond repair feasibility. [8][17]", "For device-bearing patients, include lead position and lead-valve interaction in follow-up imaging whenever TR worsens. [6]" ], "subsections": [], "table": { "caption": "", "columns": [], "rows": [] } } ], "faq": [ { "question": "Does hepatic-vein systolic flow reversal establish severe tricuspid regurgitation?", "answer": "Hepatic-vein systolic flow reversal is a corroborating marker of severe TR, but severity should be assigned using an integrated echocardiographic assessment that also incorporates quantitative measures, continuous-wave Doppler, valve anatomy, and right-heart remodeling. [5][13]" }, { "question": "What outcome should be emphasized when discussing tricuspid edge-to-edge repair?", "answer": "For appropriately selected symptomatic severe TR, emphasize expected TR reduction and improvement in health status and functional capacity. In the randomized TRILUMINATE cohort, the 1-year composite benefit was primarily driven by health-status improvement, while 12-month mortality or tricuspid-surgery freedom was similar to medical therapy. [18]" } ], "references": [ { "number": 1, "title": "Transcatheter Edge-to-Edge Repair for Severe Isolated Tricuspid ...", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jama/fullarticle/2827209", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 2, "title": "Interventions for Tricuspid Regurgitation | JAMA Cardiology", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamacardiology/fullarticle/2841799", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 3, "title": "A Review - JAMA Network", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamacardio/articlepdf/10.1001/jamacardio.2019.0535", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 4, "title": "Anatomic Relationship of the Complex Tricuspid Valve, Right ...", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamacardiology/fullarticle/2731095", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 5, "title": "Isolated tricuspid regurgitation: outcomes and therapeutic interventions | Heart", "detail": "heart.bmj.com", "url": "https://heart.bmj.com/content/104/10/798", "authors": "heart.bmj.com", "host": "heart.bmj.com" }, { "number": 6, "title": "Complications Associated With Transvenous Cardiac Implantable ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/ANNALS-25-02383", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 7, "title": "Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-021-01322-2", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 8, "title": "Evidence-based surgical management of acquired tricuspid valve disease | Nature Reviews Cardiology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/nrcardio.2013.5", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 9, "title": "Evolution and regional disparities in guideline recommendations ...", "detail": "www.cell.com", "url": "https://www.cell.com/iscience/fulltext/S2589-0042(25)02474-5", "authors": "www.cell.com", "host": "www.cell.com" }, { "number": 10, "title": "Efficacy and safety of transfemoral TAVR in pure aortic regurgitation patients: a single center study | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-025-03214-1", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 11, "title": "Tricuspid valve disease: diagnosis, prognosis and management of a ...", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41569-019-0186-1", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 12, "title": "Tricuspid regurgitation in the context of severe left-sided valvular ...", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(24)10905-X?uuid=uuid%3A3bd76694-2c48-40cd-aaa5-f96d58d2ccf1", "authors": "www.cell.com", "host": "www.cell.com" }, { "number": 13, "title": "Evaluation and Management of Right-Sided Heart Failure", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/cir.0000000000000560", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 14, "title": "Tricuspid Regurgitation: A Review of Current Interventional ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/JAHA.123.032999", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 15, "title": "3D Echocardiographic and CMR Imaging for the Assessment of ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/pdf/10.1161/circimaging.124.017638", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 16, "title": "ICHOM STANDARD DATASET - American Heart Association Journals", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/pdf/10.1161/HCQ.0000000000000128", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 17, "title": "Management of Volume Overload in Severe Atrial-Functional Tricuspid Regurgitation: Improved Feasibility of Transcatheter Edge-to-Edge Repair | JACC: Case Reports", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jaccas.2023.101776", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 18, "title": "Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized Cohort", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2024.10.086", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 19, "title": "Transcatheter Interventions for Tricuspid Regurgitation | JACC Journal Club", "detail": "www.jacc.org", "url": "https://www.jacc.org/digital-content/video/transcatheter-interventions-tricuspid-regurgitation-jacc-journal-club", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 20, "title": "Review Article Choosing Between Tricuspid Repair or Replacement", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2474870625003240", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 21, "title": "Outcomes of Octogenarians Undergoing Edge-to-Edge Transcatheter Valve Repair for Tricuspid Regurgitation: Inverse Propensity Score-Weighted Analysis - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0002914925001171", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 22, "title": "Transcatheter Therapies for Treating Tricuspid Regurgitation", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0735109716007117", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 23, "title": "Surgical edge-to-edge repair for tricuspid regurgitation: Impact of the concomitant annuloplasty - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0167527322017429", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 24, "title": "Guidelines on the management of valvular heart disease", "detail": "academic.oup.com", "url": "https://academic.oup.com/eurheartj/article/28/2/230/2887330", "authors": "academic.oup.com", "host": "academic.oup.com" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Transcatheter Edge-to-Edge Repair for Severe Isolated Tricuspid ...", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jama/fullarticle/2827209", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "Tricuspid regurgitation was quantified using a multiparametric approach according to current guidelines and recommendations. A weekly", "score": 0.534443 }, { "number": 2, "title": "Interventions for Tricuspid Regurgitation | JAMA Cardiology", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamacardiology/fullarticle/2841799", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "This Viewpoint discusses 3 randomized clinical trials on tricuspid regurgitation: TRILUMINATE, Tri.Fr, and TRISCEND II.", "score": 0.36575165 }, { "number": 3, "title": "A Review - JAMA Network", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamacardio/articlepdf/10.1001/jamacardio.2019.0535", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "Meaning Understanding the pathophysiology of tricuspid regurgitation gives insight into clinical outcomes and the timing of interventions. Anatomic Relationship", "score": 0.35999444 }, { "number": 4, "title": "Anatomic Relationship of the Complex Tricuspid Valve, Right ...", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamacardiology/fullarticle/2731095", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "Tricuspid regurgitation contributes to the pathophysiology of right-sided heart failure by increasing the RA pressure and reducing the venous", "score": 0.24254677 }, { "number": 5, "title": "Isolated tricuspid regurgitation: outcomes and therapeutic interventions | Heart", "detail": "heart.bmj.com", "url": "https://heart.bmj.com/content/104/10/798", "authors": "heart.bmj.com", "host": "heart.bmj.com", "snippet": "A comprehensive two-dimensional and Doppler echocardiogram should be performed in all patients in whom severe TR is suspected to confirm the diagnosis of severe TR as well as elucidate its aetiology. The morphology of the TV, annular size, and RV size and function should be assessed. The echocardiog", "score": 0.70214266 }, { "number": 6, "title": "Complications Associated With Transvenous Cardiac Implantable ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/ANNALS-25-02383", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "This review will also focus on 4) lead-related tricuspid regurgitation, which affects 20% to 30% of CIEDs and has become an area of intense", "score": 0.5815176 }, { "number": 7, "title": "Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-021-01322-2", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Symptomatic medical therapy and surgical reconstruction, or replacement of the tricuspid valve are recommended for the treatment of severe TR according to current guidelines10, 616–664 (2017).\"). Novel interventional therapies such as cava valve implantation are being evaluated as alternative treatm", "score": 0.47212428 }, { "number": 8, "title": "Evidence-based surgical management of acquired tricuspid valve disease | Nature Reviews Cardiology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/nrcardio.2013.5", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "## Key Points\n\nFunctional tricuspid regurgitation is the most common type of tricuspid valve (TV) disease that develops secondary to tricuspid annular and right ventricular dilatation, and is often reversible\n\nOrganic TV disease results from primary structural pathology in leaflets, subvalvular appa", "score": 0.40867847 }, { "number": 9, "title": "Evolution and regional disparities in guideline recommendations ...", "detail": "www.cell.com", "url": "https://www.cell.com/iscience/fulltext/S2589-0042(25)02474-5", "authors": "www.cell.com", "host": "www.cell.com", "snippet": "In the ACC/AHA guidelines, it ranged from 0% for tricuspid valve diseases (TVDs) and mixed valve diseases to 15.3% for aortic valve diseases (", "score": 0.400703 }, { "number": 10, "title": "Efficacy and safety of transfemoral TAVR in pure aortic regurgitation patients: a single center study | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-025-03214-1", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \nPubMed \nGoogle Scholar\n\nOtto, C. M. et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. J. Thorac. Cardiovasc. Surg. 162(2), E183–E353. (2021).\n\nArticle \nPubMed \nGoogle Scholar\n\nVahanian, A. et al. 2021 ESC/EACTS Guidelines for the management of valvul", "score": 0.3127377 }, { "number": 11, "title": "Tricuspid valve disease: diagnosis, prognosis and management of a ...", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41569-019-0186-1", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Tricuspid regurgitation is common in patients with chronic heart failure but is vastly undertreated, and its incidence is increasing,", "score": 0.29979196 }, { "number": 12, "title": "Tricuspid regurgitation in the context of severe left-sided valvular ...", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(24)10905-X?uuid=uuid%3A3bd76694-2c48-40cd-aaa5-f96d58d2ccf1", "authors": "www.cell.com", "host": "www.cell.com", "snippet": "We aimed to assess the characteristics, management and long-term prognosis of a cohort of patients with multiple valvular disease, focusing on the context of", "score": 0.1984992 }, { "number": 13, "title": "Evaluation and Management of Right-Sided Heart Failure", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/cir.0000000000000560", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "Hepatic vein flow reversal indicates severe TR, whereas leftward interatrial septal bowing also indicates RAP or volume overload. tricuspid", "score": 0.49362883 }, { "number": 14, "title": "Tricuspid Regurgitation: A Review of Current Interventional ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/JAHA.123.032999", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "With increasing severity of TR reverse systolic flow is observed in hepatic veins.18, hepatic vein reverse flow. TR causes progressive right", "score": 0.48323447 }, { "number": 15, "title": "3D Echocardiographic and CMR Imaging for the Assessment of ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/pdf/10.1161/circimaging.124.017638", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "This study highlights the clinical importance of mul- timodality imaging in the accurate assessment of tricuspid regurgitation (TR) severity, a pivotal step in", "score": 0.42835352 }, { "number": 16, "title": "ICHOM STANDARD DATASET - American Heart Association Journals", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/pdf/10.1161/HCQ.0000000000000128", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "echocardiographic variables, vena contracta. TR, tricuspid regurgitation; and VC, vena contracta. An IVC diameter <2.1 cm is considered normal. are usually", "score": 0.4081122 }, { "number": 17, "title": "Management of Volume Overload in Severe Atrial-Functional Tricuspid Regurgitation: Improved Feasibility of Transcatheter Edge-to-Edge Repair | JACC: Case Reports", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jaccas.2023.101776", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "Title: Management of Volume Overload in Severe Atrial-Functional Tricuspid Regurgitation: Improved Feasibility of Transcatheter Edge-to-Edge Repair | JACC: Case Reports\nAuthors: Andrea Scotti, Jonathan Curio, Pier Pasquale Leone, Sebastian Ludwig, Augustin Coisne, Matteo Sturla, Sandhya Murthy, Mei ", "score": 0.7373288 }, { "number": 18, "title": "Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized Cohort", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2024.10.086", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "The TRILUMINATE Pivotal trial is the first international effort to randomize patients suffering from symptomatic severe or greater TR to undergo T-TEER vs medical therapy alone. Our study of the full randomized cohort of 572 patients reported the following key findings: 1) T-TEER with TriClip showed", "score": 0.8386933 }, { "number": 19, "title": "Transcatheter Interventions for Tricuspid Regurgitation | JACC Journal Club", "detail": "www.jacc.org", "url": "https://www.jacc.org/digital-content/video/transcatheter-interventions-tricuspid-regurgitation-jacc-journal-club", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "Title: Transcatheter Interventions for Tricuspid Regurgitation | JACC Journal Club\n4. Transcatheter Interventions for Tricuspid Regurgitation | JACC Journal Club. # Transcatheter Interventions for Tricuspid Regurgitation | JACC Journal Club. In this session of JACC Journal Club, we explore cutting-e", "score": 0.8025714 }, { "number": 20, "title": "Review Article Choosing Between Tricuspid Repair or Replacement", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2474870625003240", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Transcatheter tricuspid edge-to-edge repair is both safe and effective. Anticoagulation and diuretic strategy are critical for management after transcatheter", "score": 0.767638 }, { "number": 21, "title": "Outcomes of Octogenarians Undergoing Edge-to-Edge Transcatheter Valve Repair for Tricuspid Regurgitation: Inverse Propensity Score-Weighted Analysis - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0002914925001171", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### Eur Heart J Cardiovasc Imaging\n\n### Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis\n\n### Eur Heart J\n\n### ESC/EACTS Guidelines for the management of valvular heart disease\n\n### Eur He", "score": 0.7099254 }, { "number": 22, "title": "Transcatheter Therapies for Treating Tricuspid Regurgitation", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0735109716007117", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Recently, novel transcatheter treatment options were developed for treating patients with severe TR and right heart failure with prohibitive surgical risk.", "score": 0.6907474 }, { "number": 23, "title": "Surgical edge-to-edge repair for tricuspid regurgitation: Impact of the concomitant annuloplasty - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0167527322017429", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "# Surgical edge-to-edge repair for tricuspid regurgitation: Impact of the concomitant annuloplasty. Tricuspid edge-to-edge repair showed better long-term outcomes when performed with concomitant tricuspid annuloplasty. Surgical edge-to-edge repair has been suggested for tricuspid regurgitation (TR) ", "score": 0.6765563 }, { "number": 24, "title": "Guidelines on the management of valvular heart disease", "detail": "academic.oup.com", "url": "https://academic.oup.com/eurheartj/article/28/2/230/2887330", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "TR = tricuspid regurgitation. these patients should be informed of the risks and they require careful risk assessment and very close monitoring of", "score": 0.5052006 } ], "publishedAt": "2026-09-15T23:05:01.950924+00:00", "updatedAt": "2026-09-15T23:05:01.950924+00:00", "readingMinutes": 6, "slug": "tricuspid-regurgitation" }